DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives $13.54 Average Target Price from Analysts

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has been given an average rating of “Hold” by the fifteen analysts that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $13.3846.

Several brokerages have recently issued reports on XRAY. UBS Group decreased their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, May 7th. BMO Capital Markets reiterated a “market perform” rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a report on Friday. Barrington Research set a $15.00 target price on DENTSPLY SIRONA in a research note on Monday. Citigroup started coverage on DENTSPLY SIRONA in a report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price target for the company. Finally, Mizuho dropped their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th.

DENTSPLY SIRONA Stock Down 3.8%

DENTSPLY SIRONA stock opened at $11.66 on Friday. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -4.24, a PEG ratio of 1.41 and a beta of 0.85. The company’s 50 day simple moving average is $11.81 and its 200 day simple moving average is $11.89. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07. DENTSPLY SIRONA has a fifty-two week low of $9.40 and a fifty-two week high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business’s quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts anticipate that DENTSPLY SIRONA will post 1.45 EPS for the current year.

Insider Activity at DENTSPLY SIRONA

In related news, Director Brian T. Gladden purchased 9,985 shares of the business’s stock in a transaction on Monday, June 15th. The shares were purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the completion of the purchase, the director owned 61,849 shares in the company, valued at $619,726.98. This represents a 19.25% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Brian P. Mckeon purchased 10,000 shares of DENTSPLY SIRONA stock in a transaction dated Friday, June 12th. The stock was bought at an average price of $10.12 per share, with a total value of $101,200.00. Following the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at approximately $101,200. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 35,160 shares of company stock worth $351,179. 0.46% of the stock is owned by company insiders.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in DENTSPLY SIRONA in the 2nd quarter worth $283,405,000. First Eagle Investment Management LLC raised its stake in shares of DENTSPLY SIRONA by 3.2% in the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock valued at $167,342,000 after purchasing an additional 458,744 shares during the period. AQR Capital Management LLC raised its stake in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after purchasing an additional 6,970,086 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after purchasing an additional 92,868 shares in the last quarter. Finally, Southpoint Capital Advisors LP bought a new stake in shares of DENTSPLY SIRONA in the first quarter valued at about $116,000,000. 95.70% of the stock is currently owned by institutional investors and hedge funds.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.